MTOR and mantle cell lymphoma: The anti-tumor activity of ridaforolimus, another intravenously administered mTOR inhibitor, has been evaluated in a phase II study of 52 patients with hematologic malignancies (including 9 patients with MCL) (Table 3) [43].